JP2020502116A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502116A5 JP2020502116A5 JP2019531713A JP2019531713A JP2020502116A5 JP 2020502116 A5 JP2020502116 A5 JP 2020502116A5 JP 2019531713 A JP2019531713 A JP 2019531713A JP 2019531713 A JP2019531713 A JP 2019531713A JP 2020502116 A5 JP2020502116 A5 JP 2020502116A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- group
- structural formula
- compound
- pyridinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000004193 piperazinyl group Chemical group 0.000 claims 4
- 125000003386 piperidinyl group Chemical group 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims 4
- 125000002393 azetidinyl group Chemical group 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 150000003973 alkyl amines Chemical class 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- -1 azetidineyl moieties Chemical group 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662436328P | 2016-12-19 | 2016-12-19 | |
| US62/436,328 | 2016-12-19 | ||
| US201762536367P | 2017-07-24 | 2017-07-24 | |
| US62/536,367 | 2017-07-24 | ||
| PCT/US2017/067050 WO2018118793A1 (en) | 2016-12-19 | 2017-12-18 | Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020502116A JP2020502116A (ja) | 2020-01-23 |
| JP2020502116A5 true JP2020502116A5 (enExample) | 2021-02-04 |
Family
ID=62627122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531713A Pending JP2020502116A (ja) | 2016-12-19 | 2017-12-18 | 突然変異イソクエン酸デヒドロゲナーゼの阻害およびその組成物と方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11149032B2 (enExample) |
| EP (1) | EP3555079A4 (enExample) |
| JP (1) | JP2020502116A (enExample) |
| KR (1) | KR20190092476A (enExample) |
| CN (1) | CN110291085B (enExample) |
| AU (1) | AU2017379796B2 (enExample) |
| CA (1) | CA3047136A1 (enExample) |
| WO (1) | WO2018118793A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109311863B (zh) * | 2016-06-06 | 2021-10-29 | 伊莱利利公司 | 突变型idh1抑制剂 |
| WO2019213403A1 (en) | 2018-05-02 | 2019-11-07 | Kinnate Biopharma Inc. | Inhibitors of cyclin-dependent kinases |
| AU2019291935A1 (en) * | 2018-06-29 | 2021-02-04 | Kinnate Biopharma Inc. | Inhibitors of cyclin-dependent kinases |
| CN111825666B (zh) * | 2019-04-23 | 2024-03-08 | 上海仕谱生物科技有限公司 | 二聚或多聚体形式的突变型idh抑制剂 |
| WO2022056453A1 (en) * | 2020-09-14 | 2022-03-17 | Totus Medicines Inc. | Therapeutic conjugates |
| CN120554346A (zh) * | 2024-02-28 | 2025-08-29 | 中国科学院上海药物研究所 | 一类噁唑酮取代的嘧啶胺化合物及其制备方法、药物组合物和用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030004174A9 (en) * | 2000-02-17 | 2003-01-02 | Armistead David M. | Kinase inhibitors |
| WO2008080937A1 (en) * | 2006-12-28 | 2008-07-10 | Basf Se | 2-substituted pyrimidines i in therapy |
| MX342326B (es) * | 2011-09-27 | 2016-09-26 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante. |
| CA2961793C (en) * | 2014-09-19 | 2021-03-16 | Forma Therapeutics, Inc. | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors |
| WO2017140758A1 (en) * | 2016-02-19 | 2017-08-24 | Debiopharm International S.A. | Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers |
| CN109311863B (zh) * | 2016-06-06 | 2021-10-29 | 伊莱利利公司 | 突变型idh1抑制剂 |
-
2017
- 2017-12-18 KR KR1020197019050A patent/KR20190092476A/ko not_active Abandoned
- 2017-12-18 CA CA3047136A patent/CA3047136A1/en not_active Abandoned
- 2017-12-18 AU AU2017379796A patent/AU2017379796B2/en not_active Ceased
- 2017-12-18 EP EP17882734.1A patent/EP3555079A4/en not_active Withdrawn
- 2017-12-18 US US16/467,978 patent/US11149032B2/en not_active Expired - Fee Related
- 2017-12-18 CN CN201780086231.0A patent/CN110291085B/zh not_active Expired - Fee Related
- 2017-12-18 JP JP2019531713A patent/JP2020502116A/ja active Pending
- 2017-12-18 WO PCT/US2017/067050 patent/WO2018118793A1/en not_active Ceased
-
2021
- 2021-09-12 US US17/472,646 patent/US20210403460A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020502116A5 (enExample) | ||
| JP2009536620A5 (enExample) | ||
| JP2012508252A5 (enExample) | ||
| JP2018507877A5 (enExample) | ||
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| JP2010511721A5 (enExample) | ||
| JP2020521740A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| JP2005535586A5 (enExample) | ||
| JP2019517487A5 (enExample) | ||
| JP2013512915A5 (enExample) | ||
| JP2011509309A5 (enExample) | ||
| JP2006151984A5 (enExample) | ||
| JP2020506951A5 (enExample) | ||
| JP2014503574A5 (enExample) | ||
| JP2016505586A5 (enExample) | ||
| JP2014051526A5 (enExample) | ||
| JP2017509586A5 (enExample) | ||
| JP2016531126A5 (enExample) | ||
| JP2008540554A5 (enExample) | ||
| RU2016131189A (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНДУКТОРОВ ЧЕЛОВЕЧЕСКОГО ИНТЕРФЕРОНА | |
| JP2016505614A5 (enExample) | ||
| JP2015521156A5 (enExample) | ||
| JP2011506566A5 (enExample) | ||
| JP2018529690A5 (enExample) |